Snap Inc. Chief Strategy Officer Imran Khan is leaving the company the pursue other opportunities. This has been a very difficult decision for me to make. There is never a p ..
Merck & Co's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients, marking a further a ..
Industry-leading production is just one reason investors can't seem to get enough of this pot stock. ..
Here are four reasons investors turned negative on the crane equipment company last month. ..
Counting on Social Security? These moves might set you back financially. ..
Just when I thought the Elon Musk news cycle might come back to earth for a few days, it erupted, into the stratosphere, yet again. Then Musk went on the wildly popular Joe R ..
Sep.10 -- Christopher Grisanti, chief executive officer at Grisanti Capital Management, explains why he still expects to see good things from shares of Apple Inc. He speaks wi ..
John Rutledge, Safanad chief investment officer, discusses U.S.-China relations as President Trump readies further tariffs on Chinese goods. ..
Imran Khan, Snap chief strategy officer, is stepping down from his position at the social media company. ..
Porter Bibb, MediaTech Capital Partners managing partner, discusses the saga for CBS as CEO Les Moonves leaves under new allegations of sexual misconduct and the ongoing strug ..